Age-Related Macular Degeneration (AMD) Therapeutics Market Research Report to 2019 | Industry Growth Share, Size, Future Trends, Price, Top Key Players Review, and Global Analysis by Forecast 2023-MAZZ Home
Age-Related Macular Degeneration (AMD) Therapeutics Market report also offers a basic overview of the industry including definitions, Size, classifications, applications and industry chain structure. Most importantly a complete discussion of the several factors which are driving the development of the global Age-Related Macular Degeneration (AMD) Therapeutics Market as well as those factors which are expected to hinder the growth of this Market is included.
Global “Age-Related Macular Degeneration (AMD) Therapeutics Market” Research Report contains complete industry information and changing trends in the market that allows users to spot the pin-point analysis of the market along with revenue, development and profit during the forecast period. It offers detailed study of Age-Related Macular Degeneration (AMD) Therapeutics market by using SWOT analysis. This gives comprehensive analysis of drivers, restrains and opportunities of the market.
Age-Related Macular Degeneration (AMD) Therapeutics Market analysts forecast the global Age-Related Macular Degeneration (AMD) Therapeutics market to grow at a CAGR of over 8% % during the period 2019-2023.
Request a sample copy of the report –https://www.absolutereports.com/enquiry/request-sample/14439887
Age-related macular degeneration (AMD) is a bilateral ocular disease that affects the central area of the retina known as the macula. age-related macular degeneration considers sales from both wet AMD, dry AMD.
Age-Related Macular Degeneration (AMD) Therapeutics Market Segment by Manufacturers includes:
- Amgen Inc.
- Bausch Health Companies Inc.
- F. Hoffmann-La Roche Ltd.
- Novartis AG
- Regeneron Pharmaceuticals Inc.
and many more.
Age-Related Macular Degeneration (AMD) Therapeutics Market Segment by Regions includes: North America (USA, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America, Middle East and Africa.
High prevalence of AMD
The prevalence of AMD is extremely high, owing to the presence of high-risk factors for developing the condition. Risk factors such as aging, smoking, high cholesterol, and high blood pressure are the major contributors to the development of AMD. Moreover, despite the high prevalence of AMD, no approved therapies are available in the market for the treatment of the condition. Thus, the high prevalence coupled with the huge unmet medical need of dry AMD is expected to drive the market at a CAGR of over 8% during the forecast period.
Development of gene therapy for AMD
There is a huge unmet need for safe and novel drugs to treat AMD. The currently available anti-VEGF therapies require repetitive and inconvenient intraocular injections. Owing to factors such as inconvenience and discomfort associated with frequent injections in the eye, patient compliance is a significant concern with anti-VEGF therapies. Hence, several companies are working on novel drugs against AMD, among which gene therapy is expected to cure the disease effectively. Hence, the development of gene therapy is expected to be a positive trend for the global AMD therapeutics market.
Inquire or share your questions if any before the purchasing this report – https://www.absolutereports.com/enquiry/pre-order-enquiry/14439887
Key questions answered in this report
- What will the market size be in 2023 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
Covered in this report:
The report covers the current scenario and the development prospects of the global Age-Related Macular Degeneration (AMD) Therapeutics market for 2019-2023. To determine the market size, the report considers the revenue generated from the sales of Age-Related Macular Degeneration (AMD) Therapeutics.
Purchase this Report (Price 2500 USD for a Single-User License)
Table of Contents
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
Market segmentation analysis
PART 04: MARKET SIZING
Market sizing 2018
Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
PART 06: MARKET SEGMENTATION BY TYPE
Market segmentation by type
Comparison by type
Wet AMD – Market size and forecast 2018-2023
Dry AMD – Market size and forecast 2018-2023
Market opportunity by type
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
North America – Market size and forecast 2018-2023
Europe – Market size and forecast 2018-2023
Asia – Market size and forecast 2018-2023
ROW – Market size and forecast 2018-2023
Key leading countries
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
PART 11: MARKET TRENDS
Development of gene therapy for AMD
Growing awareness about AMD
PART 12: VENDOR LANDSCAPE
PART 13: VENDOR ANALYSIS
Market positioning of vendors
Bausch Health Companies Inc.
F. Hoffmann-La Roche Ltd.
Regeneron Pharmaceuticals Inc.
PART 14: APPENDIX
List of abbreviations
Definition of market positioning of vendors
PART 15: EXPLORE TECHNAVIO
Name: Ajay More
Phone: US +1424 253 0807/ UK +44 203 239 8187
Mail id: [email protected]
Our Other Report:
Dark Chocolate Market with several features of the industry like the market size, market status, market trends and forecast, the report also offers brief information of the competitors and the specific growth opportunities with key market drivers.
Press Release Distributed by The Express Wire
To view the original version on The Express Wire visit Age-Related Macular Degeneration (AMD) Therapeutics Market Research Report to 2019 | Industry Growth Share, Size, Future Trends, Price, Top Key Players Review, and Global Analysis by Forecast 2023